Company: ARTL
Filing Date: 2025-12-11
Form Type: DEF 14A
Source: 0001640334-25-002308
Chunk: 28

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-12-11
Form: DEF 14A
Chunk 28
---
ui                 |     |                                            | 10,763 |
| Douglas Blayney, M.D.         |     |                                            |  9,210 |
| Gregory R. Reyes, M.D., Ph.D. |     |                                            |  4,388 |
| R. Martin Emanuele, Ph.D.     |     |                                            |  8,894 |
| Steven Kelly                  |     |                                            |  9,714 |
| Tamara A. Favorito            |     |                                            |  2,009 |

| (3) | 2,873 option awards outstanding as of December 31, 2024. |
| (4) | 2,556 option awards outstanding as of December 31, 2024. |
| (5) | 2,139 option awards outstanding as of December 31, 2024. |
| (6) | 2,479 option awards outstanding as of December 31, 2024. |
| (7) | 2,659 option awards outstanding as of December 31, 2024. |
| (8) | 1,139 option awards outstanding as of December 31, 2024. |

| 15 |

<div align='center'>EXECUTIVE OFFICERS</div>

Our executive officers are appointed by, and serve at the discretion of, the Board. The names of our executive officers and their ages, titles and biographies are set forth below:

| Name              |     | Age |     | Position                                                   |
| Gregory D. Gorgas |     |  61 |     | President, Chief Executive Officer, Secretary and Director |
| Mark Spring       |     |  67 |     | Chief Financial Officer and Treasurer                      |

Gregory D. Gorgas.See Corporate Governance-Continuing Directors.

Mark Spring was appointed chief financial officer, treasurer, principal financial officer and principal accounting officer in November 2025. Mr. Spring also served as a consultant to us from December 2024 to October 2025. Mr. Spring brings 30 years of experience in life sciences to his role, including financial leadership of private and public, domestic and multinational, commercial and development stage companies. Mr. Spring recently served as interim chief financial officer for LENZ Therapeutics through its reverse merger transaction and as co-founder and chief financial officer of Secura Bio, a commercial-stage oncology therapeutics company. Mr. Spring also held the role of chief financial officer for